Royal Philips NV Reports Robust European Sales Growth

Deep News05-06

Royal Philips NV announced a 4% increase in comparable sales for the first quarter. The company's headquarters in Amsterdam saw European sales rise on both a nominal and comparable basis. First-quarter nominal sales declined to 3.91 billion euros from 4.1 billion euros in the same period last year. Despite the drop in nominal revenue, the medical technology firm achieved particularly strong business growth in Western Europe. The Dutch company reported revenue of 3.91 billion euros (equivalent to 4.57 billion U.S. dollars), slightly surpassing analyst expectations of 3.88 billion euros. Meanwhile, comparable sales grew by 4% year-over-year. Royal Philips NV attributed this growth to a broad-based recovery in North American and European markets, as well as strong performance in its Personal Health division. Sales in Europe increased on both a nominal and comparable basis. Net profit for the first quarter of 2026 was 151 million euros, significantly higher than the 76 million euros recorded in the prior-year period and well above market expectations of 66 million euros. Full-Year Outlook: Royal Philips NV expects its full-year adjusted EBITA margin to be in the range of 12.5% to 13.0%. The company anticipates full-year comparable sales growth of 3% to 4.5%.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1132667921?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-06 18:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1132667921","market":"fut","top_or_hot":-1,"title":"Royal Philips NV Reports Robust European Sales Growth","media":"Deep News","content":"<p>Royal Philips NV announced a 4% increase in comparable sales for the first quarter.\nThe company's headquarters in Amsterdam saw European sales rise on both a nominal and comparable basis.\nFirst-quarter nominal sales declined to 3.91 billion euros from 4.1 billion euros in the same period last year.\nDespite the drop in nominal revenue, the medical technology firm achieved particularly strong business growth in Western Europe.\nThe Dutch company reported revenue of 3.91 billion euros (equivalent to 4.57 billion U.S. dollars), slightly surpassing analyst expectations of 3.88 billion euros.\nMeanwhile, comparable sales grew by 4% year-over-year. Royal Philips NV attributed this growth to a broad-based recovery in North American and European markets, as well as strong performance in its Personal Health division. Sales in Europe increased on both a nominal and comparable basis.\nNet profit for the first quarter of 2026 was 151 million euros, significantly higher than the 76 million euros recorded in the prior-year period and well above market expectations of 66 million euros.\nFull-Year Outlook:\nRoyal Philips NV expects its full-year adjusted EBITA margin to be in the range of 12.5% to 13.0%. The company anticipates full-year comparable sales growth of 3% to 4.5%.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Royal Philips NV Reports Robust European Sales Growth</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRoyal Philips NV Reports Robust European Sales Growth\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2026-05-06 18:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Royal Philips NV announced a 4% increase in comparable sales for the first quarter.\nThe company's headquarters in Amsterdam saw European sales rise on both a nominal and comparable basis.\nFirst-quarter nominal sales declined to 3.91 billion euros from 4.1 billion euros in the same period last year.\nDespite the drop in nominal revenue, the medical technology firm achieved particularly strong business growth in Western Europe.\nThe Dutch company reported revenue of 3.91 billion euros (equivalent to 4.57 billion U.S. dollars), slightly surpassing analyst expectations of 3.88 billion euros.\nMeanwhile, comparable sales grew by 4% year-over-year. Royal Philips NV attributed this growth to a broad-based recovery in North American and European markets, as well as strong performance in its Personal Health division. Sales in Europe increased on both a nominal and comparable basis.\nNet profit for the first quarter of 2026 was 151 million euros, significantly higher than the 76 million euros recorded in the prior-year period and well above market expectations of 66 million euros.\nFull-Year Outlook:\nRoyal Philips NV expects its full-year adjusted EBITA margin to be in the range of 12.5% to 13.0%. The company anticipates full-year comparable sales growth of 3% to 4.5%.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"","article_id":"1132667921","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1132667921","pubTimestamp":1778062849,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"Royal Philips NV announced a 4% increase in comparable sales for the first quarter. The company's headquarters in Amsterdam saw European sales rise on both a nominal and comparable basis....","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","PHG":"飞利浦","BK4082":"医疗保健设备","BK4588":"碎股"},"translate_title":"皇家飞利浦公司报告欧洲销售强劲增长","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PHG":1},"content_text":"Royal Philips NV announced a 4% increase in comparable sales for the first quarter.\nThe company's headquarters in Amsterdam saw European sales rise on both a nominal and comparable basis.\nFirst-quarter nominal sales declined to 3.91 billion euros from 4.1 billion euros in the same period last year.\nDespite the drop in nominal revenue, the medical technology firm achieved particularly strong business growth in Western Europe.\nThe Dutch company reported revenue of 3.91 billion euros (equivalent to 4.57 billion U.S. dollars), slightly surpassing analyst expectations of 3.88 billion euros.\nMeanwhile, comparable sales grew by 4% year-over-year. Royal Philips NV attributed this growth to a broad-based recovery in North American and European markets, as well as strong performance in its Personal Health division. Sales in Europe increased on both a nominal and comparable basis.\nNet profit for the first quarter of 2026 was 151 million euros, significantly higher than the 76 million euros recorded in the prior-year period and well above market expectations of 66 million euros.\nFull-Year Outlook:\nRoyal Philips NV expects its full-year adjusted EBITA margin to be in the range of 12.5% to 13.0%. The company anticipates full-year comparable sales growth of 3% to 4.5%.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1132667921","isCrawlerRequest":true}